Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6515
    -0.0004 (-0.06%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin AUD

    107,742.14
    -1,091.08 (-1.00%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6035
    +0.0001 (+0.02%)
     
  • AUD/NZD

    1.0890
    -0.0012 (-0.11%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     

Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against LifeMD, Inc. (LFMD) and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

PHILADELPHIA, April 17, 2021 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) on behalf of investors who purchased shares of the Company’s stock between January 19, 2021 and April 13, 2021, inclusive (the “Class Period”).

LifeMD investors who have suffered an investment loss in excess of $100,000 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by email at skaskela@kaskelalaw.com or online at https://kaskelalaw.com/case/lifemd-inc/, for additional information about this investigation and their legal rights and options.

According to the complaint, on April 14, 2021, Culper Research issued a report alleging that “LifeMD appears to use unlicensed doctors to dispense OTC medications, has implemented an autoshipping/autobilling scheme, failed to honor guarantees, and put in place abusive telemarketing practices.” The Culper report also alleged that several of LifeMD’s executives were previously involved in “wide ranging fraud” at Redwood Scientific, which was charged by the U.S. Federal Trade Commission for “unlawful autoshipping, abusive telemarketing, and false claims.” According to the Culper report, “[a]t LifeMD, numerous customer reviews lead us to believe that the Company has implemented the same tactics. LifeMD touts its “recurring revenue” model yet we think much of the Company’s revenues are generated under false pretenses of ‘one-time purchases.’”

Following this news, shares of LifeMD’s common stock declined $2.84 per share, or nearly 25% in value, to close on April 14, 2021 at $9.00 per share, on heavy trading volume.

IMPORTANT DEADLINE: Investors who purchased LifeMD’s securities during the Class Period may, no later than June 15, 2021, seek to be appointed as a lead plaintiff representative in the action. LifeMD investors who suffered an investment loss in excess of $100,000 are encouraged to contact Kaskela Law LLC to discuss this opportunity to actively participate in the action.

ADVERTISEMENT

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

D. Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
(484) 258 – 1585
(888) 715 – 1740
www.kaskelalaw.com
skaskela@kaskelalaw.com